Arkolith/Insider Trading/EIKN/Form 4

Wolfe Josh

Director, 10% OwnerEikon Therapeutics, Inc. (EIKN) · full profile →Form 4 · filed Feb 6, 2026
Net Buying
Open-Market Buys
$5.0M
Open-Market Sells
$0
Net Open-Market Flow
$5.0M
Transactions
15
5 non-derivative · 10 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 6, 2026Conversion(C)2.2M——2.3M
Feb 6, 2026Conversion(C)1.2M——1.3M
Feb 6, 2026Conversion(C)2.4M——2.4M
Feb 4, 2026Buy(P)139K$18.00$2.5M139K
Feb 4, 2026Buy(P)139K$18.00$2.5M139K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 6, 2026Conversion(C)531K——0
Feb 6, 2026Conversion(C)5.3M——0
Feb 6, 2026Conversion(C)3.5M——0
Feb 6, 2026Conversion(C)303K——0
Feb 6, 2026Conversion(C)1.5M——0
Feb 6, 2026Conversion(C)10.3M——0
Feb 6, 2026Conversion(C)10.0M——0
Feb 6, 2026Conversion(C)7.8M——0
Feb 6, 2026Conversion(C)2.5M——0
Feb 6, 2026Conversion(C)796K——0

Transaction Codes

C
Conversion of a derivative
P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-041549) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML